Spyre Therapeutics (Spyre Therapeutics) EV-to-Revenue : 1,168.56 (As of Apr. 27, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Spyre Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Spyre Therapeutics's enterprise value is $1,035.34 Mil. Spyre Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.89 Mil. Therefore, Spyre Therapeutics's EV-to-Revenue for today is 1,168.56.

The historical rank and industry rank for Spyre Therapeutics's EV-to-Revenue or its related term are showing as below:

SYRE' s EV-to-Revenue Range Over the Past 10 Years
Min: -154.51 Med: 16.33 Max: 1672.19
Current: 1168.56

During the past 11 years, the highest EV-to-Revenue of Spyre Therapeutics was 1672.19. The lowest was -154.51. And the median was 16.33.

SYRE's EV-to-Revenue is ranked worse than
95.84% of 1033 companies
in the Biotechnology industry
Industry Median: 7.66 vs SYRE: 1168.56

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-27), Spyre Therapeutics's stock price is $33.56. Spyre Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.23. Therefore, Spyre Therapeutics's PS Ratio for today is 144.03.

Spyre Therapeutics EV-to-Revenue Historical Data

The historical data trend for Spyre Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spyre Therapeutics EV-to-Revenue Chart

Spyre Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

7.81

-9.31

701.58

Spyre Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-9.31	-12.95	-158.42	-146.11	701.58

Competitive Comparison of Spyre Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Spyre Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spyre Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's EV-to-Revenue falls into.

Spyre Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Spyre Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	1035.342	/	0.886
	=	1,168.56

Spyre Therapeutics's current Enterprise Value is $1,035.34 Mil.
Spyre Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.89 Mil.

Spyre Therapeutics (NAS:SYRE) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Spyre Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	33.56	/	0.233
	=	144.03

Spyre Therapeutics's share price for today is $33.56.
Spyre Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23.

Spyre Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Spyre Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Spyre Therapeutics (Spyre Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spyre Therapeutics Inc (NAS:SYRE) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

221 Crescent Street, Building 23,, Suite 105, Waltham, MA, USA, 02453

Website

https://www.spyre.com

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Executives

Scott L Burrows	officer: Chief Financial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Heidy King-jones	officer: See Remarks	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Fairmount Healthcare Co-invest L.p.	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Peter Evan Harwin	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Cameron Turtle	officer: Chief Operating Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Michael Thomas Henderson	director	421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p.	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p.	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jeff Marc Goldberg	director, officer: President and CEO	C/O AKCEA THERAPEUTICS, 55 CAMBRIDGE PARKWAY, STE 100, CAMBRIDGE MA 02142
Linda L Neuman	officer: Chief Medical Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Marcio Souza	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
James Paul Kastenmayer	officer: Interim CEO & General Counsel	ONE MEDIMMUNE WAY, FLOOR ONE, AREA TWO, GAITHERSBURG MD 20879
Hanley Jr. Michael Conick	officer: Chief Commercial Officer	C/O AEGLEA THERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746